NZ754625A - Muscle performance improvement compounds - Google Patents

Muscle performance improvement compounds

Info

Publication number
NZ754625A
NZ754625A NZ754625A NZ75462517A NZ754625A NZ 754625 A NZ754625 A NZ 754625A NZ 754625 A NZ754625 A NZ 754625A NZ 75462517 A NZ75462517 A NZ 75462517A NZ 754625 A NZ754625 A NZ 754625A
Authority
NZ
New Zealand
Prior art keywords
compounds
muscle performance
components
component
muscle
Prior art date
Application number
NZ754625A
Other languages
English (en)
Inventor
Jan Willem Vrijbloed
Marina Maria Boido
Olena Butenko
Roberta Schellino
Original Assignee
Pharmafox Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmafox Therapeutics Ag filed Critical Pharmafox Therapeutics Ag
Publication of NZ754625A publication Critical patent/NZ754625A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ754625A 2016-11-29 2017-11-28 Muscle performance improvement compounds NZ754625A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Publications (1)

Publication Number Publication Date
NZ754625A true NZ754625A (en) 2023-03-31

Family

ID=58073474

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754625A NZ754625A (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Country Status (11)

Country Link
US (1) US11407799B2 (https=)
EP (1) EP3548509A1 (https=)
JP (2) JP7683901B2 (https=)
KR (1) KR102622245B1 (https=)
CN (1) CN110036024B (https=)
AU (1) AU2017367277B2 (https=)
CA (1) CA3045245A1 (https=)
GB (1) GB201620119D0 (https=)
NZ (1) NZ754625A (https=)
WO (1) WO2018100483A1 (https=)
ZA (1) ZA201903261B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110430890B (zh) 2016-11-10 2024-09-10 科乐斯疗法公司 激活素受体iia型变体及其使用方法
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
JP2023512423A (ja) * 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them
CN116171147A (zh) * 2020-07-24 2023-05-26 新加坡科技研究局 伤口愈合组合物及其用途
JP2024511315A (ja) * 2021-03-10 2024-03-13 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法
US20250064952A1 (en) * 2021-03-10 2025-02-27 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434934D1 (de) * 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
US20100004171A1 (en) 2006-08-08 2010-01-07 Bazan Nicolas G Therapeutic Methods for Neuropathic Pain
CA2661836A1 (en) 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
JP6267425B2 (ja) * 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用

Also Published As

Publication number Publication date
WO2018100483A1 (en) 2018-06-07
JP2019536818A (ja) 2019-12-19
AU2017367277B2 (en) 2021-04-01
JP2023116479A (ja) 2023-08-22
EP3548509A1 (en) 2019-10-09
CN110036024A (zh) 2019-07-19
CN110036024B (zh) 2024-05-07
JP7683901B2 (ja) 2025-05-27
GB201620119D0 (en) 2017-01-11
CA3045245A1 (en) 2018-06-07
ZA201903261B (en) 2020-02-26
KR20190085132A (ko) 2019-07-17
US20210253654A1 (en) 2021-08-19
KR102622245B1 (ko) 2024-01-05
AU2017367277A1 (en) 2019-07-04
US11407799B2 (en) 2022-08-09

Similar Documents

Publication Publication Date Title
NZ754625A (en) Muscle performance improvement compounds
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX389450B (es) Compuesto novedoso de pirimidina condensada o sal del mismo.
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
BR112018009361A8 (pt) composições e métodos para o tratamento de doenças autoimunes e de câncer
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
PH12019501425A1 (en) Human antibodies to s. aureus hemolysin a toxin
PH12015501656A1 (en) Anti-il-33 antibodies and use thereof
GEAP202114828A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
PH12017502013A1 (en) Anti-ox40 antibodies and methods of use thereof
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
WO2020021477A3 (en) Compositions and methods for treating the eye
NZ758291A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EA201691521A1 (ru) Антитела к интерлейкину-21
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA201991600A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
MX2018016118A (es) Carotenoides microbianos que afectan la composicion de la microbiota intestinal.
SA520420909B1 (ar) تثبيط بروتين رابط لـ creb (cbp)
MX2018001733A (es) Compuestos heterocíclicos de fumagillol y métodos de elaboración y uso de los mismos.
EA201990418A1 (ru) Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat)
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
SG11201805791RA (en) COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α
EA201990988A1 (ru) Антитела против chikv и пути их применения
PH12018500445A1 (en) Use of anto-cd40 antibodies for treatment of lupus nephritis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 NOV 2024 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20230828

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 NOV 2025 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20240828

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 NOV 2026 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20250828